UCB SA (UCBJY)
| Market Cap | 55.96B +58.7% |
| Revenue (ttm) | 9.09B +25.8% |
| Net Income | 1.83B +46.3% |
| EPS | 9.43 +46.5% |
| Shares Out | n/a |
| PE Ratio | 30.59 |
| Forward PE | 23.46 |
| Dividend | 0.53 (0.37%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 56,926 |
| Open | 145.32 |
| Previous Close | 142.36 |
| Day's Range | 145.32 - 147.08 |
| 52-Week Range | 87.92 - 168.76 |
| Beta | 0.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial numbers in EUR Financial StatementsNews
Cullinan jumps after UCB acquires Candid Therapeutics
Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid’s lead investigational asset, is “pos...
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
UCB to acquire Neurona Therapeutics
UCB (UCBJF) announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Th...
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila downgraded UCB (UCBJF) to Equal Weight from Overweight with an unchanged price target of EUR 260. The firm sees a balanced risk/reward at current share…
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB initiated with an Outperform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of UCB (UCBJF) with an Outperform rating and EUR 340 price target The firm launched coverage of the neuroscience biotech sector with a…
UCB price target raised to EUR 304 from EUR 255 at Goldman Sachs
Goldman Sachs raised the firm’s price target on UCB (UCBJF) to EUR 304 from EUR 255 and keeps a Buy rating on the shares.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
UCB SA Slides: 44th Annual J.P. Morgan Healthcare Conference
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
UCB price target raised to EUR 310 from EUR 270 at Barclays
Barclays raised the firm’s price target on UCB (UCBJF) to EUR 310 from EUR 270 and keeps an Overweight rating on the shares.
UCB price target raised to EUR 295 from EUR 285 at Deutsche Bank
Deutsche Bank raised the firm’s price target on UCB (UCBJF) to EUR 295 from EUR 285 and keeps a Buy rating on the shares.
UCB price target raised to EUR 300 from EUR 230 at JPMorgan
JPMorgan raised the firm’s price target on UCB (UCBJF) to EUR 300 from EUR 230 and keeps an Overweight rating on the shares.
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...
UCB removed from European Conviction List at Goldman Sachs
Goldman Sachs analysts removed UCB (UCBJF) from the firm’s European Conviction List as part of its monthly update.
UCB assumed with an Underperform at Jefferies
Jefferies assumed coverage of UCB (UCBJF) with an Underperform rating and EUR 212 price target Flagging recent slowing of U.S. volume trends, the firm sees 10%-15% downside to street Bimzelx…
UCB announces new three-year data from Phase 3 trials on BIMZELX
UCB (UCBJF), a global biopharmaceutical company, announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX in adults with active psoriatic arthritis, Ps...
UCB price target raised to EUR 290 from EUR 220 at Berenberg
Berenberg raised the firm’s price target on UCB (UCBJF) to EUR 290 from EUR 220 and keeps a Buy rating on the shares.
UCB price target raised to EUR 285 from EUR 250 at Deutsche Bank
Deutsche Bank raised the firm’s price target on UCB (UCBJF) to EUR 285 from EUR 250 and keeps a Buy rating on the shares.
UCB price target raised to EUR 240 from EUR 220 at Morgan Stanley
Morgan Stanley raised the firm’s price target on UCB (UCBJF) to EUR 240 from EUR 220 and keeps an Overweight rating on the shares.
UCB added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added UCB (UCBJF) to the firm’s European Conviction List as part of its monthly update. The firm believes UCB offers a “rare opportunity” within European biopharma to…